Skip to main
BCAX

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc. is focused on developing its bifunctional antibody, ficerafusp alfa, which targets multiple biologically relevant pathways in treating solid tumors, positioning the company for significant market capture, especially in HNSCC, where it anticipates a 35% share upon regulatory approval. The company is strategically addressing the competitive landscape of MSS mCRC by hypothesizing that dual inhibition may enhance treatment outcomes, which could lead to positive market positioning against existing therapies. Furthermore, institutional confidence in the product's potential success is bolstered by the anticipation of interim analysis updates, which may drive future growth and support a broader clinical impact.

Bears say

Bicara Therapeutics Inc. faces significant challenges regarding the efficacy and safety of its lead program, ficerafusp alfa, as underwhelming clinical results have led to a reduced probability of success in treating head and neck squamous cell carcinoma (HNSCC), now projected at only 30%. The company is expected to report a full-year net loss of $2.56 per share in 2026, indicating potential financial instability, particularly if the product fails to differentiate itself from competitive therapies and achieves limited market uptake. Additionally, various regulatory and market risks, including the possibility of negative clinical outcomes and delays in advancing to registrational trials, further compound the negative outlook for Bicara’s stock performance.

BCAX has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 9 analysts, BCAX has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.